Development of S-Nitrosothiol-based Therapy for Alzheimer's Disease

基于 S-亚硝基硫醇的阿尔茨海默病疗法的开发

基本信息

  • 批准号:
    8141069
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-04-01 至 2015-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is the most common form of dementia in the elderly, affecting about 10% of those aged 65 or over, but no treatment to delay or halt the progression of the disease is as yet available. Under the present situation where the proportion of the elderly population is progressively increasing, AD has become a significant problem for the elderly citizens including Veterans. Therefore, the study of this disease is relevant to the mission of the Veterans Administration. Recently, new evidences indicate cerebrovascular complications and impaired regional cerebral blood flow as the causative factors in AD along with its associated memory loss and behavioral changes. In turn, this evidence provides the rationale for early treatment of cerebrovascular dysfunction which is critical for delaying, slowing down or preventing the development of AD. Nitric oxide (NO) plays an essential role in the maintenance of vascular tone and hemodynamics. Currently, free NO donors, such as sodium nitroprusside and nitroglycerine, are being used in various clinical settings. However, these NO donors, releasing free NO, may not be an effective treatment for AD because the concomitant chronic inflammation and oxidative stress scavenge free NO from these donors to generate deleterious peroxynitrite. Here, we propose to evaluate the therapeutic potential of GSNO, a major transport form of NO in biological systems, for the treatment of AD. GSNO is able to induce several cell signal transduction pathways that are essential for biological action of NO via S-transnitrosylation without generation of free NO. In addition, GSNO is implicated in anti-inflammatory, anti-oxidant, and vaso-protective effects under various disease conditions. Therefore, GSNO is a promising candidate as a stand-alone therapy for cerebrovascular complications implicated in AD. In support, we have recently observed that GSNO treatment inhibited the inflammatory response and also reduced A¿ accumulation and improved impaired learning and memory performance in aged rats with chronic cerebral hypoperfusion, an animal model for vascular dysfunction associated with late-onset AD, and in transgenic mice over-expressing human A¿. On the basis of these data, the following specific aims are designed to improve therapeutic reliability of GSNO in the treatment of AD, to optimize pharmacological parameters, and to investigate mechanisms underlying the drug action(s). Specific Aim 1: To establish therapeutic efficacy and pharmacological optimal dose of GSNO therapy for cerebrovascular complications associated with Alzheimer's disease: Under this aim, we propose to optimize the efficacy of GSNO treatment against cerebrovascular complications associated with development and progression of AD pathology. Two animal models will be employed for these studies: transgenic mice producing high levels of A¿ for studies of early-onset AD and aged rats received bilateral common carotid artery occlusion (BCCAO), a clinically relevant model for human mild cognitive impairment and associated late-onset AD. Specific Aim 2: To investigate the mechanism(s) underlying GSNO therapy: Implication of anti-inflammatory and vaso-protective activities of GSNO: Under this aim, we propose to investigate the mechanism(s) underlying GSNO mediated anti-inflammatory and vaso-protective signaling cascades in brain micro-vessel endothelial cells. Focus of this aim will be to study the S-nitrosylation of cell signaling mediators regulating gene expression for inflammatory mediators and A¿ clearance across the blood brain barrier (BBB). The results from studies described here should provide a better understanding of pharmacological, biochemical and cell biological events underlying vascular pathology of AD, and the possible utility of GSNO as therapeutics for the management of AD. PUBLIC HEALTH RELEVANCE: Alzheimer's disease (AD) is the most common dementia in the elderly affecting about 10% of those aged 65 or over, for which no treatment is available yet. Under the present situation where the relative proportion of elderly is progressively increasing, AD has become a significant problem in the aging population of veterans and seniors. Therefore, the study of this disease is very relevant to the overall mission of Veterans Administration. Evidence indicates that AD implicates vascular complications leading to impaired cerebral blood flow, in turn suggesting that early intervention of vascular dysfunction would be critical as therapeutics for AD therapeutics. Here, we propose to evaluate the therapeutic potential of S-nitrosoglutathione, an endogenous nitric oxide carrier, against cerebrovascular complications associated with development of AD. We expect that this approach will lead to the development of a new strategy for the treatment of AD which will provide benefits for the healthcare of elderly Veterans and seniors.
描述(由申请人提供):

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Avtar K Singh其他文献

LOW DOSE ZIDOVUDINE (ZDV) REDUCES MEDIUM AND LONG CHAIN FATTY ACID OXIDATION IN PREGNANT AND NEONATAL RATS. † 1033
  • DOI:
    10.1203/00006450-199604001-01055
  • 发表时间:
    1996-04-01
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    George M Johnson;Mahesh Gupta;Karl Krember;Avtar K Singh;Inderjit Singh
  • 通讯作者:
    Inderjit Singh
FATPY ACID METABOLISM IN REYE'S SYNDROME
雷耶综合征中的脂肪酸代谢
  • DOI:
    10.1203/00006450-198704010-01003
  • 发表时间:
    1987-04-01
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Inderjit Singh;Yoshihiro Yoshida;Avtar K Singh;Fred W Mecklenberq;C P Darby
  • 通讯作者:
    C P Darby
5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) attenuates the expression of LPS- and Aβ peptide-induced inflammatory mediators in astroglia
  • DOI:
    10.1186/1742-2094-2-21
  • 发表时间:
    2005-09-20
  • 期刊:
  • 影响因子:
    10.100
  • 作者:
    Kamesh R Ayasolla;Shailendra Giri;Avtar K Singh;Inderjit Singh
  • 通讯作者:
    Inderjit Singh

Avtar K Singh的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Avtar K Singh', 18)}}的其他基金

Mechanism of Vascular Impairment in Neurocognitive Disorders
神经认知障碍中血管损伤的机制
  • 批准号:
    10553093
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Mechanism of Vascular Impairment in Neurocognitive Disorders
神经认知障碍中血管损伤的机制
  • 批准号:
    10343797
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Development of S-Nitrosothiol-based Therapy for Alzheimer's Disease
基于 S-亚硝基硫醇的阿尔茨海默病疗法的开发
  • 批准号:
    8398957
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Nitrosylation Mechanisms for Protection Against Neurovascular Inflammatory Injury
预防神经血管炎症损伤的亚硝基化机制
  • 批准号:
    8458156
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Nitrosylation Mechanisms for Protection Against Neurovascular Inflammatory Injury
预防神经血管炎症损伤的亚硝基化机制
  • 批准号:
    8259741
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Mechanisms of Krabbe Disease Pathobiology and Therapy
克拉伯病病理学和治疗机制
  • 批准号:
    8109021
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Mechanisms of Krabbe Disease Pathobiology and Therapy
克拉伯病病理学和治疗机制
  • 批准号:
    8448639
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Mechanisms of Krabbe Disease Pathobiology and Therapy
克拉伯病病理学和治疗机制
  • 批准号:
    8643297
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Nitrosylation Mechanisms for Protection Against Neurovascular Inflammatory Injury
预防神经血管炎症损伤的亚硝基化机制
  • 批准号:
    8652841
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Development of S-Nitrosothiol-based Therapy for Alzheimer's Disease
基于 S-亚硝基硫醇的阿尔茨海默病疗法的开发
  • 批准号:
    8696815
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Interplay between Aging and Tubulin Posttranslational Modifications
衰老与微管蛋白翻译后修饰之间的相互作用
  • 批准号:
    24K18114
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The Canadian Brain Health and Cognitive Impairment in Aging Knowledge Mobilization Hub: Sharing Stories of Research
加拿大大脑健康和老龄化认知障碍知识动员中心:分享研究故事
  • 批准号:
    498288
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
EMNANDI: Advanced Characterisation and Aging of Compostable Bioplastics for Automotive Applications
EMNANDI:汽车应用可堆肥生物塑料的高级表征和老化
  • 批准号:
    10089306
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Collaborative R&D
Baycrest Academy for Research and Education Summer Program in Aging (SPA): Strengthening research competencies, cultivating empathy, building interprofessional networks and skills, and fostering innovation among the next generation of healthcare workers t
Baycrest Academy for Research and Education Summer Program in Aging (SPA):加强研究能力,培养同理心,建立跨专业网络和技能,并促进下一代医疗保健工作者的创新
  • 批准号:
    498310
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
関節リウマチ患者のSuccessful Agingに向けたフレイル予防対策の構築
类风湿性关节炎患者成功老龄化的衰弱预防措施的建立
  • 批准号:
    23K20339
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Life course pathways in healthy aging and wellbeing
健康老龄化和福祉的生命历程路径
  • 批准号:
    2740736
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Studentship
NSF PRFB FY 2023: Connecting physiological and cellular aging to individual quality in a long-lived free-living mammal.
NSF PRFB 2023 财年:将生理和细胞衰老与长寿自由生活哺乳动物的个体质量联系起来。
  • 批准号:
    2305890
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Fellowship Award
I-Corps: Aging in Place with Artificial Intelligence-Powered Augmented Reality
I-Corps:利用人工智能驱动的增强现实实现原地老龄化
  • 批准号:
    2406592
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
McGill-MOBILHUB: Mobilization Hub for Knowledge, Education, and Artificial Intelligence/Deep Learning on Brain Health and Cognitive Impairment in Aging.
McGill-MOBILHUB:脑健康和衰老认知障碍的知识、教育和人工智能/深度学习动员中心。
  • 批准号:
    498278
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
Welfare Enhancing Fiscal and Monetary Policies for Aging Societies
促进老龄化社会福利的财政和货币政策
  • 批准号:
    24K04938
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了